Most Recent
A man who says he was falsely accused by a Seven journalist of spitting at an alleged rape victim of rugby league footballer Jarryd Hayne must hand over key CCTV footage he claims vindicates him in his defamation suit against Seven.
A judge has signed off on a $4.7 million settlement in two investor class actions against collapsed sandalwood producer Quintis, two year after an earlier settlement was scuttled as group members kicked off an insurance dispute in pursuit of a better return.
Twitter personality Alan Davison, who runs the account Stock Swami, has admitted he misled lawyers for mining investor Tolga Kumova and deliberately failed to obey court orders for discovery in cross-examination during a defamation trial.
The lead applicant in an unsuccessful class action over the Carwoola bushfire has avoided indemnity costs sought by insurer CGU and has won a 40 per cent reduction in the amount of legal costs it will have to cover for the defendant.
A judge has told Forum Finance director Vince Tesoriero to “revisit” evidence about his true financial position if he wants to win the release of $1.25 million to pay for his defence in Westpac’s fraud case against him, amid concerns about whether he has made full disclosure to the court.
The corporate regulator has reprimanded a liquidator for “serious” breaches of independence rules, and has directed the insolvency practitioner to refuse appointments until next year.
A judge has tossed a class action brought by a self-represented applicant against Wilson Security, saying class actions should not be run without lawyers.
A litigation funder has reaped $7.5 million from the sale of a 20 per cent stake in a shareholder class action against the Commonwealth Bank of Australia over the bank's allegedly lax money laundering compliance.
Channel Seven has asked the Federal Court to terminate a Test cricket and Big Bash League broadcast agreement with Cricket Australia due to alleged contract breaches.
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi's patent for a biosimilar of blockbuster arthritis drug Humira.